Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies by modifying existing FDA-approved cancer drugs to improve safety-efficacy profiles. Key pipeline assets include PCS6422 (NGC-Cap, a capecitabine combination in Phase 2 for breast cancer) and PCS11T (NGC-Iri, an irinotecan analog in preclinical development). The company also has two non-oncology assets (PCS12852 for gastroparesis and PCS499 for glomerular disease) being evaluated for out-licensing, and has adopted a digital asset treasury strategy.
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001493152-26-011204 | EDGAR | 64K words |
| 2025-03-20 | 2024-12-31 | 0001641172-25-000070 | EDGAR | 74K words |
| 2024-03-29 | 2023-12-31 | 0001493152-24-011976 | EDGAR | 61K words |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009730 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001493152-22-008156 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001493152-21-006807 | EDGAR | — |
| 2020-03-06 | 2019-12-31 | 0001493152-20-003534 | EDGAR | — |
| 2019-03-28 | 2018-12-31 | 0001493152-19-004137 | EDGAR | — |
| 2018-04-16 | 2017-12-31 | 0001493152-18-005248 | EDGAR | — |
| 2017-09-25 | 2016-12-31 | 0001393905-17-000290 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001493152-26-038334 | EDGAR | 17K words |
| 2025-11-06 | 2025-09-30 | 0001493152-25-021069 | EDGAR | 18K words |
| 2025-08-07 | 2025-06-30 | 0001493152-25-011685 | EDGAR | 15K words |
| 2025-05-08 | 2025-03-31 | 0001641172-25-009252 | EDGAR | 13K words |
| 2024-10-30 | 2024-09-30 | 0001493152-24-043058 | EDGAR | 17K words |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031622 | EDGAR | 16K words |
| 2024-05-10 | 2024-03-31 | 0001493152-24-018648 | EDGAR | 15K words |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040472 | EDGAR | 19K words |
| 2023-08-10 | 2023-06-30 | 0001493152-23-027551 | EDGAR | 17K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017001 | EDGAR | 14K words |
| 2022-11-08 | 2022-09-30 | 0001493152-22-030942 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001493152-22-022063 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001493152-26-036032 | EDGAR | 1K words |
| 2026-07-29 | 0001493152-26-035099 | EDGAR | 2K words |
| 2026-02-19 | 0001493152-26-007469 | EDGAR | 1K words |
| 2026-01-07 | 0001493152-26-000733 | EDGAR | 1K words |
| 2025-12-15 | 0001493152-25-027680 | EDGAR | 1K words |
| 2025-09-12 | 0001493152-25-013108 | EDGAR | 1K words |
| 2025-09-10 | 0001493152-25-012966 | EDGAR | 1K words |
| 2025-09-02 | 0001493152-25-012567 | EDGAR | 1K words |
| 2025-08-25 | 0001641172-25-025421 | EDGAR | 1K words |
| 2025-08-08 | 0001493152-25-011775 | EDGAR | 1K words |
254 total filings indexed. 222 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001533743 |
| Ticker | PCSA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Vero Beach, FL |
| Website | https://www.processapharmaceuticals.com |
| Listed | 2013-10-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PCSA (~200 tokens, structured JSON with cryptographic provenance)